Menu
Home
Log in / Register
 
Home arrow Health arrow Cognitive impairment and dementia in Parkinson disease
Source

Conclusion

The diagnosis of dementia associated with PD is a two-step process. The first step involves exclusion of other causes of mental dysfunction and an evaluation of how much ADL are impaired due to cognitive deficits. A detailed history, an adequate evaluation of cognitive functions, behavioural symptoms, and ADL are the main diagnostic tools, whereas auxiliary examinations are of less importance in standard cases. The application of clinical diagnostic criteria for PD-D facilitates the diagnostic process. Although not necessary when dementia with typical features for PD-D develops in the context of established PD, differential diagnosis with regard to other causes of parkinsonism associated with dementia may be required in complex cases.

References

  • 1. Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol 2003; 2: 229-37.
  • 2. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the Movement Disorder Society task force. Mov Disord 2007; 22: 2314-24.
  • 3. Barton B, Grabli D, Bernard B, et al. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson’s disease with dementia. Mov Disord 2012; 27: 248-53.
  • 4. Isella V, Mapelli C, Siri C, et al. Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson’s disease dementia. Parkinsonism Relat Disord 2014; 20: 32-6.
  • 5. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-9.
  • 6. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717-25.
  • 7. Mioshi E, Dawson K, Mitchell J, et al. The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006; 21: 1078-5.
  • 8. Reyes MA, Perez-Lloret S, Roldan Gerschcovich E, et al. Addenbrooke’s Cognitive Examination validation in Parkinson’s disease. Eur J Neurol 2009; 16: 142-7.
  • 9. Kalbe E, Calabrese P, Kohn N, et al. Screening for cognitive deficits in Parkinson’s disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord 2008; 14: 93-101.
  • 10. Mahieux F, Fenelon G, Flahault A, et al. Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998; 64: 178-83.
  • 11. Dubois B, Slachevsky A, Litvan I, et al. The FAB: a frontal assessment battery at bedside. Neurology 2000; 55: 1621-6.
  • 12. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356-64.
  • 13. Mattis S. Dementia rating scale. Odessa, FL: Psychological Assessment Resources Inc., 1988.
  • 14. Kaszas B, Kovacs N, Balas I, et al. Sensitivity and specificity of Addenbrooke’s Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: 553-6.
  • 15. Emre M, Poewe W, De Deyn P et al. Long-term safety of rivastigmine in Parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol 2014; 37: 9-16.
  • 16. Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson’s disease. Neurology 2003; 61: 1222-8.
  • 17. Pagonabarraga J, Kulisevsky J, Llebaria G, et al. Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Mov Disord 2008; 23: 998-1005.
  • 18. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
  • 19. Martinez-Martin P. Dementia in Parkinson’s disease: usefulness of the pill questionnaire. Mov Disord 2013; 28: 1832-7.
  • 20. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(Suppl. 2): S33-S39.
  • 21. Gelinas I, Gauthier L, McIntyre M, et al. Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471-81.
  • 22. Burton EJ, McKeith IG, Burn DJ, et al. Brain atrophy rates in Parkinson’s disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005; 20: 1571-6.
  • 23. Burton EJ, McKeith IG, Burn DJ, et al. Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies amnd controls. Brain 2004; 127: 791-800.
  • 24. Bissessur S, Tissingh G, Wolters EC, et al. rCBF SPECT in Parkinson’s disease patients with mental dysfunction. J Neural Transm Suppl 1997; 50: 25-30.
  • 25. Firbank MJ, Colloby SJ, Burn DJ, et al. Regional cerebral blood flow in Parkinson’s disease with and without dementia. Neuroimage 2003; 20: 1309-19.
  • 26. Peppard RF, Martin WR, Carr GD, et al. Cerebral glucose metabolism in Parkinson’s disease with and without dementia. Arch Neurol 1992; 49: 1262-8.
  • 27. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Eur J Neurol 2007; 14: 1357-62.
  • 28. O’Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004; 61: 919-25.
  • 29. Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155: 60-7.
  • 30. Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2001; 71: 583-8.
  • 31. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease.

An [11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501-8.

  • 32. Rowe CC, Ng S, Ackermann U, et al. Imaging P-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-25.
  • 33. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB-PET. J Neurol Neurosurg Psychiatry 2008; 79: 1331-8.
  • 34. Mollenhauer B. Quantification of a-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson’s disease? Parkinsonism Relat Disord 2014; 20(Suppl. 1): S76-S79.
  • 35. Leverenz JB, Watson GS, Shofer J, et al. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord 2011; 17: 61-4.
  • 36. Beyer MK, Alves G, Hwang KS, et al. Cerebrospinal fluid Ap levels correlate with structural brain changes in Parkinson’s disease. Mov Disord 2013; 28: 302-10.
  • 37. Kaerst L, Kuhlmann A, Wedekind D, et al. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson’s disease, and Alzheimer’s disease. J Alzheimers Dis 2014; 38: 63-73.
  • 38. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22: 1689-707.
  • 39. Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C, et al. Dementia associated with Parkinson’s disease: applying the Movement Disorder Society Task Force criteria. Parkinsonism Relat Disord 2011; 17: 621-4.
  • 40. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27: 349-56.
  • 41. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology and biomarkers. Neurology 2007; 68: 812-19.
  • 42. Lippa CF, Emre M. Characterizing clinical phenotypes: the Lewys in their life or the life of their Lewys?. Neurology 2006; 67: 1910-11.
  • 43. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-24.
  • 44. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-72.
 
Source
Found a mistake? Please highlight the word and press Shift + Enter  
< Prev   CONTENTS   Next >
 
Subjects
Accounting
Business & Finance
Communication
Computer Science
Economics
Education
Engineering
Environment
Geography
Health
History
Language & Literature
Law
Management
Marketing
Mathematics
Political science
Philosophy
Psychology
Religion
Sociology
Travel